«

»

Cassava Sciences Announces Positive Results In Phase 2 Trial Of New Alzheimer’s Drug

The drug, sumifilam, targets a new protein in Alzheimer’s disease called Filamen A.

Read the full post at Forbes - Healthcare
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive